Russell D. Hull, MBBS, MSc, Graham F. Pineo, MD, Rollin F

Slides:

Advertisements

Similar presentations

Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis Jeffrey S. Berger, MD, MS, David L. Brown, MD, Richard C. Becker, MD The.

Advertisements

Impact of a Clinical Pharmacist Stress Ulcer Prophylaxis Management Program on Inappropriate Use in Hospitalized Patients Mitchell S. Buckley, PharmD,

Paul D. Stein, MD, Fadi Matta, MD, Mary J. Hughes, DO

Steven Baroletti, PharmD, MBA, Shelley Hurwitz, PhD, Nicole A. S

Bleeding Toes in Diabetic Neuropathy

The Effect of Smoking on the Risk of Sciatica: A Meta-analysis

Long-term Low-Molecular-Weight Heparin versus Usual Care in Proximal-Vein Thrombosis Patients with Cancer Russell D. Hull, MBBS, MSc, Graham F. Pineo,

Shelley R. Salpeter, MD, FACP, Andrew J. Wall, MD, Nicholas S. Buckley

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD,

An Evidence-based Guide for Obesity Treatment in Primary Care

An Unusual Cause of Leg Ulcerations

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Chirag Bavishi, MD, MPH,

Impact of More Restrictive Blood Transfusion Strategies on Clinical Outcomes: A Meta- analysis and Systematic Review Shelley R. Salpeter, MD, Jacob S.

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD,

Richard V. Milani, MD, Carl J. Lavie, MD, Robert M

Bleeding Toes in Diabetic Neuropathy

Alexander A. Leung, MD, MPH, Finlay A. McAlister, MD, MSc, Samuel R. G

Paul D. Stein, MD, Russell D. Hull, MBBS, MSc, Fadi Matta, MD, Abdo Y

An Evidence-based Guide for Obesity Treatment in Primary Care

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

Samy Suissa, PhD, Abbas Kezouh, PhD, Pierre Ernst, MD, MSc

Matthew I. Worthley, MBBS, PhD, FRACP, Fiona M

30-Day Readmissions After an Acute Kidney Injury Hospitalization

Systematic Review of the Mediterranean Diet for Long-Term Weight Loss

Systematic Review and Meta-analysis of Adverse Events of Low-dose Aspirin and Clopidogrel in Randomized Controlled Trials Kenneth R. McQuaid, MD, Loren.

Russell D. Hull, MBBS, MSc, Jane Liang, MSc, Grace Townshend, MSc

Venous Thromboembolism with Chronic Liver Disease

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials Giulia Renda, MD, PhD, Marta.

Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease Nina Raju, MD, MsC, Magdalena Sobieraj-Teague, MBBS, Jack Hirsh, MD,

Steven Baroletti, PharmD, MBA, Shelley Hurwitz, PhD, Nicole A. S

Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer

Marc Carrier, MD, MSc, Alok A

Long-term Low-Molecular-Weight Heparin versus Usual Care in Proximal-Vein Thrombosis Patients with Cancer Russell D. Hull, MBBS, MSc, Graham F. Pineo,

Russell D. Hull, MBBS, MSc, Graham F. Pineo, MD, Rollin F

Robert Goulden, MBBS, MSc, MPhil, MA The American Journal of Medicine

Rosuvastatin Is Transferred into Human Breast Milk: A Case Report

Andre J. Gauri, MD, Andrew Davis, MD, Thomas Hong, MD, Martin C

Do Factor V Leiden and Prothrombin G20210A Mutations Predict Recurrent Venous Thromboembolism in Older Patients? Marie Méan, MD, Andreas Limacher, PhD,

The Reply The American Journal of Medicine

Hong-Tao Tie, MD, Rui Shi, MD The American Journal of Medicine

Diagnostic and Therapeutic Yield of Endoscopy in Patients with Elevated INR and Gastrointestinal Bleeding Joanna M. Peloquin, MD, Siamak M. Seraj, MD,

Lifetime Risk of Venous Thromboembolism in Two Cohort Studies

Carlos Aguilar, MD, Valentin del Villar, MD

Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin Keitaro Senoo, MD, Marco Proietti,

Interaction of Physical Activity and Body Mass Index on Mortality in Coronary Heart Disease: Data from the Nord-Trøndelag Health Study Trine Moholdt,

The Natural Course of Microalbuminuria among African Americans with Type 2 Diabetes: A 3-Year Study Mohamed G. Atta, MD, MPH, Kesha Baptiste-Roberts,

How I treat cancer-associated venous thromboembolism

Does Methylphenidate Reduce the Symptoms of Chronic Fatigue Syndrome?

Stop Talking ‘Dirty’: Clinicians, Language, and Quality of Care for the Leading Cause of Preventable Death in the United States John F. Kelly, PhD, Sarah.

Prevalence and Risk Factors for Erectile Dysfunction in the US

Nilay S. Shah, MD, MPH, David Leonard, PhD, Carrie E

Age Differences in Treatment and Control of Hypertension in US Physician Offices, : A Serial Cross-sectional Study Anna Gu, MD, PhD, Yu Yue,

To Reduce Stroke with PFO Closure, Respect the Shunt

Effect of Folic Acid, with or without Other B Vitamins, on Cognitive Decline: Meta- Analysis of Randomized Trials David S. Wald, MA, MRCP, MD, Anuradhani.

Purnema Madahar, MD, Cristina M. Gonzalez, MD, MEd

Pneumocystis Pneumonia Complicated by Extensive Diffuse Pneumatoceles

One-way Versus Two-way Text Messaging on Improving Medication Adherence: Meta- analysis of Randomized Trials David S. Wald, MD, FRCP, Shahena Butt, MSc,

Devraj Sukul, MD, Shashank S. Sinha, MD, MSc, Andrew M

A Post-cure Complication

Plasma Lactescence in Acute Pancreatitis

Risk of Falls and Major Bleeds in Patients on Oral Anticoagulation Therapy Jacques Donzé, MD, MSc, Carole Clair, MSc, MD, Balthasar Hug, MD, MBA, MPH,

Combining Antiplatelet and Antithrombotic Therapy (Triple Therapy): What Are the Risks and Benefits? Luis Alejandro Asencio, MD, Jennifer J. Huang, DO,

Rebecca D. Chason, Joan S. Reisch, PhD, Don C. Rockey, MD

The Economic Burden of Hyponatremia: Systematic Review and Meta-Analysis Giovanni Corona, MD, PhD, Corinna Giuliani, MD, Gabriele Parenti, MD, PhD, Giorgio.

Falls in Older Adults: Risk Assessment, Management and Prevention

Emily G. McDonald, MD, MSc, Ramy R. Saleh, MD, Todd C. Lee, MD, MPH

David Tian, MD, Ram Jhingan Mohan, MD, Gary Stallings, MD

Jay S. Kaufman, PhD, Sam Harper, PhD The American Journal of Medicine

Preoperative Thienopyridine Use and Outcomes after Surgery: A Systematic Review Anita G. Au, MD, Sumit R. Majumdar, MD MPH, Finlay A. McAlister, MD MSc

Hypophosphatemia: Diagnostic Significance in Legionnaires’ Disease

Presentation transcript:

Self-Managed Long-Term Low-Molecular-Weight Heparin Therapy: The Balance of Benefits and Harms Russell D. Hull, MBBS, MSc, Graham F. Pineo, MD, Rollin F. Brant, PhD, Andrew F. Mah, BSc, Natasha Burke, BSc, Richard Dear, MD, Turnly Wong, MD, Roy Cook, MD, Susan Solymoss, MD, Man-Chiu Poon, MD, MSc, Gary Raskob, PhD The American Journal of Medicine Volume 120, Issue 1, Pages 72-82.e3 (January 2007) DOI: 10.1016/j.amjmed.2006.03.030 Copyright © 2007 Elsevier Inc. Terms and Conditions

Figure 1 Participant flow chart. The American Journal of Medicine 2007 120, 72-82.e3DOI: (10.1016/j.amjmed.2006.03.030) Copyright © 2007 Elsevier Inc. Terms and Conditions

Figure 2 Time to event analysis for patients who had recurrent venous thromboembolism At 3 months, of 737 patients, 18 of 369 patients receiving tinzaparin (4.9%) had recurrent venous thromboembolism compared with 21 of 368 (5.7%) receiving usual care (absolute difference, −0.8%, 95% CI, −4.1-2.4). IV = intravenous; LMWH = low-molecular-weight heparin. The American Journal of Medicine 2007 120, 72-82.e3DOI: (10.1016/j.amjmed.2006.03.030) Copyright © 2007 Elsevier Inc. Terms and Conditions

Figure 3 Time to event analysis for patients who had hemorrhagic complications. A: All bleeding. Bleeding occurred in 48 of 369 patients (13.0%) receiving LMWH and 73 of 368 patients (19.8%) receiving heparin and warfarin (P = .011; risk ratio = 0.66). B: Major bleeding. Major bleeding occurred in 12 of 369 patients (3.3%) in the LMWH group and in 17 of 368 patients (4.6%) receiving heparin and warfarin (risk ratio = 0.70; absolute difference −1.4, 95% CI, −4.3-1.4). C: Minor bleeding. Minor bleeding occurred in 36 of 369 patients (9.8%) receiving LMWH and in 56 of 368 patients (15.2%) receiving heparin and warfarin (P = .022; risk ratio = 0.64). IV = intravenous; LMWH = low-molecular-weight heparin. The American Journal of Medicine 2007 120, 72-82.e3DOI: (10.1016/j.amjmed.2006.03.030) Copyright © 2007 Elsevier Inc. Terms and Conditions

Figure 4 Prevalence of bleeding over time. The occurrence of bleeding according to time course of study therapy for each group is shown for major and minor bleeding complications. The pattern of the time of presentation of major bleeding differed significantly between groups (P = .034). New major bleeding events occurred throughout study treatment for patients in the usual-care group receiving warfarin but did not present after day 23 in the LMWH group (P = .034). New minor bleeding episodes occurred throughout the study treatment interval for both treatment groups. LMWH = low-molecular-weight heparin. The American Journal of Medicine 2007 120, 72-82.e3DOI: (10.1016/j.amjmed.2006.03.030) Copyright © 2007 Elsevier Inc. Terms and Conditions

Figure 5 *Treatment duration 3 months. †Treatment duration 3 to 6 months. ‡Treatment duration 6 months. LMWH = low-molecular-weight heparin; CI = confidence interval; LMWH regimen: T = treatment dose; P = prophylactic dose; M = reduced maintenance dose. The American Journal of Medicine 2007 120, 72-82.e3DOI: (10.1016/j.amjmed.2006.03.030) Copyright © 2007 Elsevier Inc. Terms and Conditions

The American Journal of Medicine 2007 120, 72-82. e3DOI: (10. 1016/j The American Journal of Medicine 2007 120, 72-82.e3DOI: (10.1016/j.amjmed.2006.03.030) Copyright © 2007 Elsevier Inc. Terms and Conditions